Pharmacy Drugs
Recent Posts
- Beta Blockers May Increase Risk For Surgical Anemia Complications
- Alimera Announces Positive Results From The Two Phase 3 FAME(TM) Trials Of Iluvien(R) In Patients With Diabetic Macular Edema
- Lytix Biopharma AS Announces Regulatory Approval By Norwegian And Swedish Authorities To Commence Phase I Clinical Trial Of OncoporeTM In Cancer
- NPA Responds To Quality Accounts Consultation, UK
- Novelos Therapeutics’ (NVLT.OB) CEO Is Eyeing “Revolutionary” Phase III Study Results
Random Posts
- Addex Partner Starts First-Ever Clinical Trial Of An MGluR Positive Allosteric Modulator
- National Pharmacy Association Calls For Zero Increase In RPSGB Retention Fees - UK
- Randomized Controlled Trial Shows Circumcision Does Not Reduce Male-To-Female HIV Transmission
- Chembio Awarded Three-Year $3MM NIH SBIR Phase II Grant To Complete DPP(R) Test For Human Leptospirosis
- Pfizer To Give Away 70 Of Its Most Widely Prescribed Drugs To Those Who Lost Jobs
- Poxel SAS Set Up To Find Innovative Solutions For Metabolic Diseases Management
- Patients With Compulsive Hair Pulling Disorder Reported Feeling Much Improved After Taking Supplement
- Clinical Activity Of TMC207 Shows ATP-Synthase Is A Viable Target For Treatment Of TB
- Reducing Cardiovascular Events: International Insulin Drug Trial
- Australian Medical Association Urges Careful Use Of Anti-viral Medicines
FDA Accepts Arno Therapeutics’ IND For AR-12 A PDK1 Inhibitor That Blocks The PI3K/Akt Pathway
Posted by: admin in Pharmacy Drugs on November 23rd, 2009
Arno Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on oncology therapeutics, announced that the U.S.